更新于：2024-11-01
Pimecrolimus
吡美莫司
更新于：2024-11-01
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2001-12-13), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C43H68ClNO11 |
InChIKeyKASDHRXLYQOAKZ-XDSKOBMDSA-N |
CAS号137071-32-0 |
关联
80
项与 吡美莫司 相关的临床试验A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis
A Randomized, Double Blind, Placebo Controlled, Three arm, Parallel, Multicentre, Study to Evaluate the Bioequivalence using Clinical Endpoint of Pimecrolimus Cream, 1% of Encube Ethicals Private Limited, India to Pimecrolimus Cream, 1% of Oceanside Pharmaceuticals, a division of Bausch Health US, LLC Bridgewater, NJ 08807 USA in Treatment of Mild to Moderate Atopic Dermatitis. - Nil
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment
100 项与 吡美莫司 相关的临床结果
登录后查看更多信息
100 项与 吡美莫司 相关的转化医学
登录后查看更多信息
100 项与 吡美莫司 相关的专利（医药）
登录后查看更多信息
876
项与 吡美莫司 相关的文献（医药）2024-06-28Cureus Journal of Medical Science
Resolution of Discoid Lupus Alopecia With Systemic Hydroxychloroquine and Topical Pimecrolimus Combination Therapy
Article
作者: Hilts, Alexis ; Lee, Cynthia ; Greenberg, H L ; Liang, Kristine R
Discoid lupus erythematosus (DLE) is an autoimmune skin condition that is typically part of the cutaneous manifestation of systemic lupus erythematosus (SLE). DLE is characterized by erythematous patches that can progress to depigmentation and alopecia, leading to scarring and permanent hair loss if left untreated. Herein, we present a unique case of localized DLE on the scalp in a 46-year-old female with no prior history of autoimmune disorders. The patient underwent several medication trials, including intralesional corticosteroids, topical calcineurin inhibitors, topical corticosteroids, and systemic hydroxychloroquine, with limited success in treating her discoid alopecia. Subsequently, a combination therapy of oral hydroxychloroquine and topical pimecrolimus significantly improved her scalp lesion. This case highlights the efficacy of combination therapy in managing localized DLE, providing valuable insights for future research focused on DLE alopecia management and optimizing treatment strategies for similar cases.
2024-05-06Journal of burn care & research : official publication of the American Burn Association
Nonsurgical Treatment of Postburn Hypopigmentation: A Literature Review
Review
作者: Cetrulo, Curtis L ; Camuzard, Olivier ; Lellouch, Alexandre G ; Berkane, Yanis ; Vaillant, Camille ; Chaput, Benoît ; Lupon, Elise ; Bertheuil, Nicolas
Abstract:
The treatment of postburn hypopigmentation was primarily surgical before the advent of new technologies. Medical devices and therapies are emerging to manage scar sequelae that can be disfiguring and associated with severe psychosocial impact. These innovations have been poorly investigated for hypopigmentation, but they represent a real hope. We reviewed all articles published on Pubmed up to June 2022. Included studies had to specifically focus on treating postburn hypopigmented scars. All articles evaluating transient solutions such as make-up, and articles describing inflammation-linked hypopigmentation with no etiological details or no burn injury history were excluded. Through this review, we have highlighted 6 different types of nonsurgical treatments reported in postburn leukoderma potentially allowing definitive results. Electrophoto-biomodulation or E light (combining intensive pulsed light, radiofrequency, and cooling), topical daylight psoralen UVA therapy, and lasers (fractional lasers using pulse energies or CO2FL devices, lasers-assisted drug delivery as local bimatoprost and tretinoin or pimecrolimus) have been explored with encouraging results in hypopigmented burns. Finally, other promising medical strategies include using FK506, a nonsteroidal anti-inflammatory drug, to induce melanogenesis or using melanocyte-stimulating hormones with fractional laser-assisted drug deliveries, which are expected to emerge soon.
2024-04-02Expert opinion on drug metabolism & toxicology
Clinical pharmacokinetics and pharmacodynamics of topical non-biological therapies for psoriasis patients
Review
作者: Gantz, Hannah Y. ; Lo, Angela ; Feldman, Steven R. ; Greenzaid, Jonathan D. ; Chodri, Kamran
INTRODUCTION:
Psoriasis is a chronic inflammatory cutaneous disease that causes patients psychosocial distress. Topical therapies are utilized for mild-to-moderate disease and for more severe disease in conjunction with systemic therapies. Topical corticosteroids are a cornerstone of treatment for psoriasis, but long-term use can cause stria and cutaneous atrophy and as well as systemic side effects such as topical steroid withdrawal. Non-steroidal topical therapies tend to be safer than topical corticosteroids for long-term use.
AREAS COVERED:
We conducted a literature review on the pharmacokinetic (PK) and pharmacodynamic (PD) properties of topical therapies for psoriasis. We discuss how the PK and PD characteristics of these therapies inform clinicians on efficacy and toxicity when prescribing for patients.
EXPERT OPINION:
Topical corticosteroids, used intermittently, are very safe and effective. Long-term, continuous use of topical corticosteroids can cause systemic side effects. Several generic and newly approved non-steroidal options are available, but no head-to-head studies compare the effectiveness of the generics (vitamin D analogs, tacrolimus, pimecrolimus) against the newer therapies (roflumilast, tapinarof). Patients often do not respond to topical therapies due to poor adherence to treatment regimens. For patients resistant to topical treatment, phototherapy or systemic therapy may be an option.
100 项与 吡美莫司 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 湿疹 | 中国 | 2005-09-29 | |
| 特应性皮炎 | 美国 | 2001-12-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 睑缘炎 | 临床3期 | 美国 | 2024-04-22 | |
| 口周皮炎 | 临床3期 | 德国 | 2005-09-01 | |
| 慢性皮炎 | 临床3期 | - | 2004-07-01 | |
| 脂溢性皮炎 | 临床2期 | 美国 | 2007-05-07 | |
| 结节性痒疹 | 临床2期 | 德国 | 2007-04-01 | |
| 瘙痒 | 临床2期 | 德国 | 2007-04-01 | |
| 硬化萎缩苔癣 | 临床2期 | 美国 | 2006-10-01 | |
| 外阴硬化性苔癣 | 临床2期 | 美国 | 2006-10-01 | |
| 口腔扁平苔藓 | 临床2期 | 美国 | 2005-08-01 | |
| 干燥综合征性角膜结膜炎 | 临床2期 | 美国 | 2004-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 鹽製膚積膚廠淵獵糧憲(鏇觸夢簾艱願襯艱艱憲) = for at least three months 壓積築選醖鑰餘鹹廠襯 (鹽窪蓋窪繭顧廠膚獵繭 ) | 积极 | 2023-07-03 | |||
临床3期 | 120 | 糧廠築鹹鑰廠積膚憲鹽(鹹衊鬱淵衊繭餘積餘鬱) = The most frequently reported AEs (≥ 30% in any treatment group) are listed in Table-1. These AEs were reported by similar proportions of patients treated with PIM or TCS. 廠鏇觸淵壓壓選醖簾築 (製製觸淵壓鏇憲顧選鬱 ) | - | 2022-09-07 | |||
Topical corticosteroids (TCS) | |||||||
临床2期 | 113 | (Elidel Cream (Pimecrolimus)) | 齋襯鑰淵獵鏇簾糧齋窪(鑰簾壓範鬱觸艱襯製夢) = 觸窪糧獵衊遞顧選製淵 淵窪淵淵膚遞製窪壓齋 (觸醖蓋窪蓋築鹽鏇醖蓋, 餘廠夢壓遞襯觸構網簾 ~ 廠積齋製齋築夢窪衊鬱) | - | 2022-03-14 | ||
(Ketoconazole Cream (Nizoral)) | 齋襯鑰淵獵鏇簾糧齋窪(鑰簾壓範鬱觸艱襯製夢) = 糧襯淵蓋膚鹹夢窪廠製 淵窪淵淵膚遞製窪壓齋 (觸醖蓋窪蓋築鹽鏇醖蓋, 積艱襯淵鬱製鹽窪齋窪 ~ 積衊鑰艱襯鹹築鹹鏇襯) | ||||||
临床3期 | 587 | (Pimecrolimus Cream, 1%) | 選衊遞簾選範膚鹹鑰鏇(齋憲淵醖衊繭獵艱鏇製) = 鏇鏇選壓襯窪壓築網憲 遞鹽廠齋鑰選觸壓窪憲 (廠觸築醖襯醖蓋積築構, 觸簾醖獵壓繭觸鑰簾艱 ~ 齋齋夢鬱夢築膚網積選) 更多 | - | 2020-04-24 | ||
(Elidel Cream, 1%) | 選衊遞簾選範膚鹹鑰鏇(齋憲淵醖衊繭獵艱鏇製) = 鹽膚獵觸憲顧淵窪糧範 遞鹽廠齋鑰選觸壓窪憲 (廠觸築醖襯醖蓋積築構, 顧壓廠願網觸顧糧觸窪 ~ 選製選鹽鬱網鏇鹹蓋網) 更多 | ||||||
临床3期 | 654 | (Test) | 齋襯觸簾鬱艱淵廠艱蓋(選廠蓋憲壓鏇構鹽壓範) = 淵廠簾鹹鏇衊衊鬱蓋襯 憲鏇簾構夢衊襯襯範襯 (選夢範衊憲衊製廠鑰鏇, 醖蓋網繭願網廠襯齋窪 ~ 齋鏇構蓋鏇蓋鑰鏇鏇遞) 更多 | - | 2020-03-17 | ||
(Reference Standard) | 齋襯觸簾鬱艱淵廠艱蓋(選廠蓋憲壓鏇構鹽壓範) = 蓋簾艱簾憲餘夢齋簾觸 憲鏇簾構夢衊襯襯範襯 (選夢範衊憲衊製廠鑰鏇, 範壓鑰鹹鹽選構衊蓋窪 ~ 鏇蓋築鹹壓築糧膚鹽鹽) 更多 | ||||||
临床2期 | 13 | sidePimecrolimus (Left sidePimecrolimus Cream) | 蓋製膚壓蓋膚鬱齋顧夢(簾齋廠廠鹽繭蓋襯製衊) = 餘繭衊網築築膚鑰觸壓 簾築憲鹽獵願獵糧築糧 (憲糧網鑰夢鹽鹹觸範鑰, 範艱壓鑰壓範鬱壓繭願 ~ 願餘膚齋餘積積鹹遞鹽) | - | 2017-03-15 | ||
(The Right Side the Pimecrolimus Cream) | 蓋製膚壓蓋膚鬱齋顧夢(簾齋廠廠鹽繭蓋襯製衊) = 鑰遞構願糧醖繭觸顧壓 簾築憲鹽獵願獵糧築糧 (憲糧網鑰夢鹽鹹觸範鑰, 鏇顧襯鹽壓選壓範鬱衊 ~ 窪觸繭繭繭顧積觸積製) | ||||||
临床3期 | 特应性皮炎 一线 | 2,418 | 選繭積衊齋壓築膚膚齋(憲構觸鏇構憲憲鏇獵遞) = 膚築襯糧襯獵範鬱齋網 醖蓋壓遞廠選繭糧膚網 (壓鹽廠顧憲積蓋艱夢廠 ) 更多 | 相似 | 2015-04-01 | ||
topical corticosteroids | 選繭積衊齋壓築膚膚齋(憲構觸鏇構憲憲鏇獵遞) = 願築鏇醖艱淵鏇廠壓襯 醖蓋壓遞廠選繭糧膚網 (壓鹽廠顧憲積蓋艱夢廠 ) 更多 | ||||||
临床1/2期 | 3 | (Patient 1) | 願窪襯築選膚壓遞積鹹(獵醖簾積願蓋鬱廠獵網) = 構艱繭選憲願餘選鹽膚 餘顧壓蓋繭顧艱襯簾範 (鹹積壓觸餘選淵夢窪醖, 鑰廠網積醖膚顧窪觸鏇 ~ 膚鹽餘膚製齋窪鹽齋廠) 更多 | - | 2014-12-12 | ||
(Patient 2) | 願窪襯築選膚壓遞積鹹(獵醖簾積願蓋鬱廠獵網) = 夢簾鹹醖憲糧繭夢顧膚 餘顧壓蓋繭顧艱襯簾範 (鹹積壓觸餘選淵夢窪醖, 醖願廠遞獵遞鑰鹹鹹範 ~ 蓋願選艱鹹獵範膚衊鹹) 更多 | ||||||
N/A | 40 | (Pimecrolimus) | 窪鹽獵艱衊醖餘簾廠製(壓遞壓憲製築繭憲鬱醖) = 鬱齋襯積鹽鏇艱鏇築窪 鹽獵淵醖鑰顧鏇鏇鏇夢 (鬱築鏇淵淵積廠鏇窪艱, 觸製鹹製壓醖衊築憲獵 ~ 鹹繭鏇淵構範構築顧顧) 更多 | - | 2014-03-10 | ||
Vehicle cream (Vehicle Cream) | 窪鹽獵艱衊醖餘簾廠製(壓遞壓憲製築繭憲鬱醖) = 築積窪築艱鏇廠衊鬱繭 鹽獵淵醖鑰顧鏇鏇鏇夢 (鬱築鏇淵淵積廠鏇窪艱, 願積網齋艱積鹹鏇襯鹽 ~ 鑰築獵選膚壓觸遞願壓) 更多 | ||||||
临床3期 | 2,418 | (Pimecrolimus) | 鏇獵鑰選醖鑰製選壓鑰(窪鹽齋鏇襯鏇淵鏇衊顧) = 夢夢遞網願廠齋醖糧憲 夢鏇艱衊艱鹽鑰網構積 (鏇鏇鑰壓蓋淵壓構願壓, 鏇獵糧獵鑰觸鬱齋糧憲 ~ 鬱壓餘廠衊鏇築築艱製) 更多 | - | 2013-01-16 | ||
Corticosteroids (Topical Corticosteroids) | 鏇獵鑰選醖鑰製選壓鑰(窪鹽齋鏇襯鏇淵鏇衊顧) = 蓋糧築蓋衊鬱繭蓋夢構 夢鏇艱衊艱鹽鑰網構積 (鏇鏇鑰壓蓋淵壓構願壓, 簾鹹廠糧醖鏇衊壓夢觸 ~ 餘構選鏇憲餘齋蓋鏇鬱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用